Physician profile
Mary Moyer
NPI 1356450043
$3,264.40
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $1,488 · 2023: $22.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $490.48 | 2019-2020 | |
| Amgen INC. | $376.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $326.00 | 2019-2020 | |
| Allergan, INC. | $252.04 | 2019-2020 | |
| Lilly USA, LLC | $168.89 | 2019-2020 | |
| Amarin Pharma, INC. | $158.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $144.90 | 2019-2020 | |
| Pfizer INC. | $90.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.73 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $54.54 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $44.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.34 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.15 | 2019-2020 | |
| Therapeuticsmd, INC. | $42.29 | 2020 | |
| Sanofi-Aventis U.S. LLC | $39.51 | 2019-2020 | |
| Abbvie INC. | $39.10 | 2019-2020 | |
| Eisai INC. | $33.36 | 2020 | |
| Sanofi Pasteur INC. | $29.18 | 2019-2020 | |
| Abbott Laboratories | $22.16 | 2023 | Freestyle Libre 2 |
| Exeltis, USA INC. | $18.60 | 2020 | |
| Daiichi Sankyo INC. | $14.52 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.14 | 2020 | |
| Upsher-Smith Laboratories LLC | $13.06 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Moyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.